Labcorp is a U.S.-based laboratory services company operating two businesses: clinical diagnostics (Dx, ~78% of revenue) and biopharma laboratory services (BLS, ~22% of revenue). The Dx business processes lab tests ordered by physicians, hospitals, and other healthcare providers, offering a broad menu of routine tests (blood counts, cholesterol, thyroid) as well as specialty and esoteric tests in oncology, women's health, autoimmune disease, and neurology. Patients access Labcorp through over 2,200 patient service centers and more than 7,000 in-office phlebotomists embedded in physician offices. Dx earns revenue on a fee-for-service basis, with volume and price/mix as the key drivers. A persistent headwind is government reimbursement pressure, particularly from PAMA, which resets Medicare lab fees to private payer rates. The BLS segment helps pharma and biotech companies develop and test new drugs. The larger BLS sub-business, Central Laboratory, provides lab testing for clinical trials globally across ~100 countries and is backlog-driven with long-duration contracts. The smaller Early Development sub-business provides preclinical testing services and is currently being restructured. Labcorp's growth strategy centers on acquiring hospital outreach lab operations to add patient volume, and expanding specialty testing in oncology, women's health, and neurology — areas growing faster than the broader diagnostics market. Longer-term, Labcorp is targeting cell and gene therapy trials, direct-to-consumer testing, and international diagnostics expansion.